VEGFA and pachyonychia congenita: Bevacizumab and other inhibitors capable of inhibiting VEGF, such as Sunitinib, will be evaluated for treatment of mCRPC (NCT01803503) [53] and should also be explored in conjunction with T cell-based immunotherapeutic strategies for patients with PC.